Treasurer of the State of North Carolina Purchases 2,379 Shares of Qiagen (NYSE:QGEN)

Treasurer of the State of North Carolina raised its position in shares of Qiagen (NYSE:QGENFree Report) by 2.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 105,444 shares of the company’s stock after purchasing an additional 2,379 shares during the quarter. Treasurer of the State of North Carolina’s holdings in Qiagen were worth $4,579,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. Toronto Dominion Bank bought a new stake in shares of Qiagen during the third quarter valued at approximately $41,000. Lindbrook Capital LLC increased its holdings in shares of Qiagen by 21.6% in the 4th quarter. Lindbrook Capital LLC now owns 1,335 shares of the company’s stock worth $58,000 after purchasing an additional 237 shares in the last quarter. Blue Trust Inc. lifted its holdings in shares of Qiagen by 253.9% during the fourth quarter. Blue Trust Inc. now owns 3,974 shares of the company’s stock valued at $161,000 after purchasing an additional 2,851 shares in the last quarter. Aigen Investment Management LP purchased a new stake in shares of Qiagen during the fourth quarter valued at $211,000. Finally, Cerity Partners LLC purchased a new stake in shares of Qiagen during the fourth quarter valued at $220,000. 70.00% of the stock is owned by hedge funds and other institutional investors.

Qiagen Stock Performance

Shares of QGEN opened at $43.99 on Tuesday. Qiagen has a 52 week low of $34.74 and a 52 week high of $47.70. The company has a quick ratio of 1.45, a current ratio of 1.84 and a debt-to-equity ratio of 0.25. The stock has a market cap of $10.04 billion, a price-to-earnings ratio of 29.50, a PEG ratio of 3.65 and a beta of 0.42. The business has a 50-day simple moving average of $42.53 and a two-hundred day simple moving average of $43.46.

Qiagen (NYSE:QGENGet Free Report) last released its earnings results on Monday, April 29th. The company reported $0.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.02. Qiagen had a net margin of 17.38% and a return on equity of 12.59%. The company had revenue of $459.00 million during the quarter, compared to analyst estimates of $453.91 million. During the same period in the prior year, the firm posted $0.53 EPS. The firm’s quarterly revenue was down 5.4% compared to the same quarter last year. On average, analysts expect that Qiagen will post 2.09 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on QGEN shares. Morgan Stanley upgraded shares of Qiagen from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $49.48 to $51.00 in a research note on Friday, February 16th. Citigroup dropped their target price on shares of Qiagen from $61.86 to $60.00 and set a “buy” rating on the stock in a report on Thursday, February 8th. Stifel Nicolaus lowered their price target on Qiagen from $55.00 to $45.00 and set a “hold” rating on the stock in a report on Wednesday, May 1st. Finally, JPMorgan Chase & Co. raised their price target on Qiagen from $50.00 to $52.00 and gave the stock an “overweight” rating in a research note on Thursday, February 8th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, Qiagen has an average rating of “Moderate Buy” and an average price target of $50.95.

Read Our Latest Research Report on Qiagen

About Qiagen

(Free Report)

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.

Further Reading

Institutional Ownership by Quarter for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.